HC Wainwright Issues Pessimistic Forecast for MLYS Earnings

Key Points

• HC Wainwright trimmed its near-term outlook for Mineralys Therapeutics, lowering Q2 2026 EPS estimates to ($0.54) from ($0.50) and cutting other 2026–2028 projections as well.
• Despite the more cautious earnings forecast, the firm kept a Buy rating and a $56 price target on MLYS, implying upside from current levels.
• Mineralys recently beat quarterly EPS estimates, reporting ($0.47) per share versus consensus expectations of ($0.51), while the stock has also drawn mixed analyst views and recent insider selling.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Investment analysts at HC Wainwright lowered their Q2 2026 earnings per share estimates for Mineralys Therapeutics in a research report issued to clients and investors on Thursday, May 7th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($0.54) per share for the quarter, down from their previous forecast of ($0.50). HC Wainwright currently has a "Buy" rating and a $56.00 price objective on the stock. The consensus estimate for Mineralys Therapeutics' current full-year earnings is ($2.29) per share. HC Wainwright also issued estimates for Mineralys Therapeutics' Q3 2026 earnings at ($0.61) EPS, Q4 2026 earnings at ($0.70) EPS, FY2026 earnings at ($2.33) EPS, FY2027 earnings at ($2.84) EPS, FY2028 earnings at ($1.52) EPS, FY2029 earnings at $0.92 EPS and FY2030 earnings at $3.73 EPS.

A number of other research firms have also issued reports on MLYS. Bank of America boosted their price objective on Mineralys Therapeutics from $46.00 to $51.00 and gave the company a "buy" rating in a research note on Friday, March 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Mineralys Therapeutics in a research note on Tuesday, April 21st. Jefferies Financial Group reiterated a "hold" rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a research note on Friday, March 13th. TD Cowen started coverage on Mineralys Therapeutics in a research note on Monday, April 27th. They set a "buy" rating on the stock. Finally, Wall Street Zen lowered Mineralys Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $49.14.

Mineralys Therapeutics Stock Performance

NASDAQ:MLYS opened at $29.54 on Monday. Mineralys Therapeutics has a 52-week low of $12.59 and a 52-week high of $47.65. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of -14.41 and a beta of 0.49. The business's fifty day moving average is $27.15 and its 200 day moving average is $33.14.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.04.

Insiders Place Their Bets

In other Mineralys Therapeutics news, insider David Malcom Rodman sold 14,058 shares of the company's stock in a transaction dated Monday, April 13th. The stock was sold at an average price of $26.54, for a total value of $373,099.32. Following the transaction, the insider directly owned 76,140 shares in the company, valued at $2,020,755.60. This represents a 15.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jon Congleton sold 75,000 shares of the company's stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $26.27, for a total value of $1,970,250.00. Following the completion of the transaction, the chief executive officer owned 705,051 shares in the company, valued at $18,521,689.77. This represents a 9.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 160,120 shares of company stock valued at $4,270,828 over the last 90 days. 18.94% of the stock is owned by insiders.

Hedge Funds Weigh In On Mineralys Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Hudson Bay Capital Management LP bought a new position in Mineralys Therapeutics in the 3rd quarter worth about $2,873,000. SG Americas Securities LLC increased its stake in Mineralys Therapeutics by 130.7% in the 4th quarter. SG Americas Securities LLC now owns 230,795 shares of the company's stock worth $8,376,000 after acquiring an additional 130,758 shares during the last quarter. Vanguard Group Inc. increased its stake in Mineralys Therapeutics by 29.8% in the 3rd quarter. Vanguard Group Inc. now owns 3,018,999 shares of the company's stock worth $114,480,000 after acquiring an additional 692,550 shares during the last quarter. Citigroup Inc. increased its stake in Mineralys Therapeutics by 501.7% in the 3rd quarter. Citigroup Inc. now owns 163,168 shares of the company's stock worth $6,187,000 after acquiring an additional 136,050 shares during the last quarter. Finally, Farallon Capital Management LLC bought a new position in Mineralys Therapeutics in the 3rd quarter worth about $63,442,000. 84.46% of the stock is currently owned by institutional investors.

Key Headlines Impacting Mineralys Therapeutics

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Mineralys Therapeutics and maintained a $56 price target, which can help support investor confidence despite the earnings revisions.
• Neutral Sentiment: The firm still sees long-term earnings potential, forecasting a swing to profitability later in the decade, including $0.92 EPS in FY2029 and $3.73 EPS in FY2030.
• Negative Sentiment: HC Wainwright lowered estimates for multiple periods, including Q2 2026, Q3 2026, Q4 2026, and FY2026-FY2028, signaling a more cautious near-term outlook for earnings.
• Negative Sentiment: Wall Street Zen reportedly downgraded the stock to Sell, adding another bearish headline that may weigh on sentiment. Article Title

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.